Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | Director | September 24, 2026 | October 05, 2026 |
| CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050 | Chief Medical Officer | May 12, 2020 | May 13, 2020 |
| Dare Bioscience, Inc.CERU · Entity 7799 | SVP, Chief Medical Officer | January 05, 2017 | January 09, 2017 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | June 11, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date September 24, 2026 · Filed October 05, 2026
This filing explicitly reported no securities owned.
CONSTELLATION PHARMACEUTICALS INC
Report date May 12, 2020 · Filed May 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,884 |
Ending reported balance
After 2020-05-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-12 · Exercise / conversion · Acquired 9,357 · Balance 25,241 Row 2 · 2020-05-12 · Sale · Disposed 9,357 · Balance 15,884 F1: These trades were made pursuant to a Rule 10b5-1 trading plan. F2: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2027-07-10 | Direct | 99,663 |
Reported balance
After 2020-05-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-12 · Exercise / conversion · Disposed 9,357 · Balance 99,663 F3: This option was granted on July 11, 2017, and has vested as to 25% of the shares underlying the option as of July 10, 2018 with the remainder vesting quarterly through July 10, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: These trades were made pursuant to a Rule 10b5-1 trading plan.
F2: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This option was granted on July 11, 2017, and has vested as to 25% of the shares underlying the option as of July 10, 2018 with the remainder vesting quarterly through July 10, 2021.
Dare Bioscience, Inc.
Report date January 05, 2017 · Filed January 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-04 | Direct | 60,000 |
Reported balance
After 2017-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-05 · Grant · Acquired 60,000 · Balance 60,000 F1: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-04 | Direct | 150,000 |
Reported balance
After 2017-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-05 · Grant · Acquired 150,000 · Balance 150,000 F2: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017.
F2: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019.
PUMA BIOTECHNOLOGY, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,000 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-11 · Grant · Acquired 27,000 · Balance 54,000 F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Row 2 · 2026-06-12 · Sale · Disposed 27,000 · Balance 27,000 F2: Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
F2: Adoption date of referenced 10b5-1(c) plan is: 03-12-2025
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 00:13 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,000 | $7.20 | $194,310.90 |
DisclosureSEC source: 0001437749-26-020706 · rdgdoc.xml · nonDerivative · entry 2 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,000 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 00:13 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020706 · rdgdoc.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,000 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 23:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,000 | $3.40 | $91,800.00 |
DisclosureSEC source: 0001437749-25-020717 · rdgdoc.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,000 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 03/12/2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.34 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 14, 2025 00:18 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020362 · rdgdoc.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 01:22 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-021020 · rdgdoc.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:23 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,000 | $3.33 | $89,818.20 |
DisclosureSEC source: 0001437749-24-020570 · rdgdoc.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-15-2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.2801 to $3.5401, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:03 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-017606 · rdgdoc.xml · nonDerivative · entry 2 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,000 F3 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:03 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,000 | $3.45 | $93,279.60 |
DisclosureSEC source: 0001437749-23-017606 · rdgdoc.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.42 to $3.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:55 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,858 | $2.63 | $73,302.76 |
DisclosureSEC source: 0001437749-22-015538 · rdgdoc.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.554 to $2.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 20:26 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-015296 · rdgdoc.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,858 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 15, 2021 Filed Jun 18, 2021 00:35 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 27,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041781 · doc4.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,858 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:14 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 40,993 | $11.17 | $457,756.53 |
DisclosureSEC source: 0001209191-21-040710 · doc4.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.08 to $11.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:34 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 10,000 | $9.89 | $98,878.00 |
DisclosureSEC source: 0001209191-20-036622 · doc4.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,993 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 00:08 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 25,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036126 · doc4.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,993 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:30 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,357 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001562180-20-003589 · primarydocument.xml · derivative · entry 3 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,663 Underlying: Common Stock · 9,357 shares Expires 2027-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 11, 2017, and has vested as to 25% of the shares underlying the option as of July 10, 2018 with the remainder vesting quarterly through July 10, 2021. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:30 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 9,357 | $50.18 | $469,488.41 |
DisclosureSEC source: 0001562180-20-003589 · primarydocument.xml · nonDerivative · entry 2 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,884 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:30 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 9,357 | $5.51 | $51,557.07 |
DisclosureSEC source: 0001562180-20-003589 · primarydocument.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 16:54 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $36.06 | $0.00 |
DisclosureSEC source: 0000899243-20-004899 · doc4.xml · derivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2020, and the shares underlying the option vest in equal quarterly installments through February 14, 2024, subject to continued service. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:28 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,232 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001562180-19-005422 · primarydocument.xml · derivative · entry 6 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,020 Underlying: Common Stock · 27,232 shares Expires 2027-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on July 11, 2017, and has vested as to 25% of the shares underlying the option as of July 10, 2018 with the remainder vesting quarterly through July 10, 2021. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:28 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 5,451 | $35.11 | $191,394.42 |
DisclosureSEC source: 0001562180-19-005422 · primarydocument.xml · nonDerivative · entry 5 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,884 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:28 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 10,899 | $30.14 | $328,536.19 |
DisclosureSEC source: 0001562180-19-005422 · primarydocument.xml · nonDerivative · entry 4 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,335 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:28 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 5,451 | $25.18 | $137,255.63 |
DisclosureSEC source: 0001562180-19-005422 · primarydocument.xml · nonDerivative · entry 3 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,234 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:28 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 5,431 | $20.01 | $108,662.36 |
DisclosureSEC source: 0001562180-19-005422 · primarydocument.xml · nonDerivative · entry 2 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,685 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:28 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 27,232 | $5.51 | $150,048.32 |
DisclosureSEC source: 0001562180-19-005422 · primarydocument.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2019 Filed Jun 13, 2019 00:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 19,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036576 · doc4.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,245 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 16:54 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0000899243-19-006926 · doc4.xml · derivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This option was granted on March 7, 2019, and the shares underlying the option vest in equal quarterly installments through March 7, 2023, subject to continued service. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 16:46 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 6,801 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000899243-18-031227 · doc4.xml · derivative · entry 4 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,866 Underlying: Common Stock · 6,801 shares Expires 2027-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 11, 2017, and is schedule to vest (i) as to 9,083 shares underlying the option in equal quarterly installments from July 10, 2017 through July 10, 2021 and (ii) as to 63,584 shares underlying the option in equal quarterly installments from July 19, 2018 through July 19, 2022. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 16:46 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 9,083 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000899243-18-031227 · doc4.xml · derivative · entry 3 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,252 Underlying: Common Stock · 9,083 shares Expires 2027-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on July 11, 2017, and has vested as to 25% of the shares underlying the option as of July 10, 2018 with the remainder vesting quarterly through July 10, 2021. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 16:46 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 6,801 | $5.51 | $37,473.51 |
DisclosureSEC source: 0000899243-18-031227 · doc4.xml · nonDerivative · entry 2 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 16:46 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 9,083 | $5.51 | $50,047.33 |
DisclosureSEC source: 0000899243-18-031227 · doc4.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 17:40 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 19,075 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0000899243-18-020281 · doc4.xml · derivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,075 Underlying: Common Stock · 19,075 shares Expires 2028-07-18 F1 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest in equal quarterly installments through July 19, 2022, subject to continued service. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 23:16 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 5,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037883 · doc4.xml · nonDerivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,822 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 12, 2017 Filed Jun 15, 2017 01:19 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 7,604 | $0.00 Strike: $79.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040003 · doc4.xml · derivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,604 Underlying: Common Stock · 7,604 shares Expires 2027-06-11 F1 · derivative.exercise_date: The option vests in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 22:17 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002984 · doc4.xml · derivative · entry 2 Senderowicz Adrian · CIK 0001616230 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 22:17 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002984 · doc4.xml · derivative · entry 1 Senderowicz Adrian · CIK 0001616230 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 22:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $40.10 | $0.00 |
DisclosureSEC source: 0001209191-16-150634 · doc4.xml · derivative · entry 1 Senderowicz Adrian · CIK 0001616230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-11-13 F1 · derivative.exercise_date: The vesting commencement date ("VCD") of the option is November 14, 2016. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the VCD and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the VCD thereafter, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.